Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Venetoclax plus Obinutuzumab in Chronic Lymphocytic Leukemia
2021-001037-39Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AbbVie Inc. Primary endpoint: Primary efficacy endpoint (ORR in Cohort 1). Started Oct 2021; status: active.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2021-001037-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001037-39.